Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News

FDA OKs Drug to Treat Neurologic Symptoms in Hunter Syndrome

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

FDA Seeks New Warning for Certain Parkinson's Drugs

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish Lawmakers Vote Against Allowing Assisted Dying

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

Little Evidence of Cannabis Efficacy for Psychiatric Illness

A new review shows insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders.

Prenatal Antiseizure Med Exposure: Risks Vary by Agent

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, with variation across individual agents.

Anxiety and Depression May Raise Risk for Aneurysm Rupture

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

Todays Updates

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Todays Updates

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Latest News

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

A new review shows insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders.

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, with variation across individual agents.

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

News All Time

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

Recommended News For You

Report provides global picture of wide inequalities in care for women's cancers

We Can Advance Our Patients' Healing by One Step With 1,000 Paper Cranes.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

Pulled Myeloma Drug Improves Survival in Trial

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

Prostate Cancer Treatment Associated With Long-Term Complications

Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.

Recommended Articles For You

Hypercoagulable State: Factors that Contribute to Blood Clots  

Tazemetostat: A Promising New Treatment for Cancer 

Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment 

Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?

2.

'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested

3.

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.

4.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

5.

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

1.

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer

2.

Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment

3.

Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care

4.

AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data

5.

Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part II

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

3.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

4.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

5.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot